|
|
Victoza (liraglutide) (type 2 diabetes mellitus) liraglutide, an analog of human GLP-1 and acts as
a GLP-1 receptor agonist. Liraglutide increases
intracellular cyclic AMP (cAMP) leading to insulin release in the presence
of elevated glucose concentrations. Actemra (tocilizumab) Actemra is a recombinant
humanized anti-human interleukin 6 (IL-6) receptor monoclonal
antibody of the immunoglobulin IgG1 kappa. It binds specifically to IL6
receptors. IL6 is a pro-inflammatory cytokine produced by a variety of cell
types, including T- and B-cells,
lymphocytes, monocytes and fibroblasts. Actemra us specifically
indicated for the treatment of adult patients with moderately to severely
active rheumatoid
arthritis who have had an
inadequate response to one or more TNF antagonist therapies Ampyra (dalfampridine) Ampyra (dalfampridine) is a
potassium channel blocker that enhances conduction in damaged nerves. The
exact mechanism by which dalfampridine exerts its therapeutic effect has
not been fully elucidated. Ampyra is specifically inidicated as a treatment
to improve walking in patients with multiple
sclerosis Adcirca (tadalafil) Embeda is specifically
indicated for the management of moderate to severe pain when a
continuous, around-the-clock opioid analgesic is needed for an extended
period of time Saphris (asenapine) Saphris (asenapine) is
a sublingual psychotropic agent. The exact
mechanism of action is unknown. However, it has been suggested that the
efficacy of asenapine in schizophrenia is mediated through a combination of
antagonist activity at D2 and 5-HT2A receptors. Saphris is specifically indicated for the acute treatment
of schizophrenia in adults and for the acute treatment of manic or
mixed episodes associated with
bipolar 1 disorder
with or without psychotic features in adults Onglyza (saxagliptin) Onglyza (saxagliptin) is an
orally-active inhibitor of the DPP4 enzyme. D-PP4 inhibitors are a class of
compounds that work by affecting the action of natural hormones in the body
called incretins. Incretins decrease blood sugar by increasing consumption
of sugar by the body, mainly through increasing insulin production in the
pancreas, and by reducing production of sugar by the liver. Onglyza is specifically indicated as an adjunct to
diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus Adcirca (tadalafil) is an oral
inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for
the degradation of cyclic guanosine monophosphate (cGMP). Pulmonary
hypertension is the result of upregulation of PDE5 gene expression, causing
vasoconstriction in the lung. Inhibition of PDE5 by tadalafil increases the
concentrations of cGMP resulting in elaxation of pulmonary vascular smooth
muscle cells and vasodilation of the pulmonary vascular bed. Adcirca is specifically indicated for the
treatment of pulmonary
arterial
hypertension Bepreve (bepotastine besilate
ophthalmic solution) Bepreve
is specifically indicated for the treatment of itching associated with
signs and symptoms of allergic conjunctivitis Embeda (morphine sulfate and naltrexone
hydrochloride) Embeda is an extended-release oral
formulation of morphine sulfate and naltrexone
hydrochloride. Morphine sulfate is an agonist and naltrexone
hydrochloride is an antagonist at the
mu-opioid receptor. Morphine provides analgesic and sedative effects while
naltrexone hydrochloride reverses the subjective and analgesic effects.
